摘要
目的探讨哮喘合并反复呼吸道感染(RRI)经规律吸入糖皮质激素(ICS)症状控制不理想的儿童联用脾氨肽(复可托)口服的临床疗效及安全性。方法采用随机、双盲法将2004年8月至2005年8月在本院收治的56例哮喘合并RRI经系统ICS治疗控制不佳的患儿分为2组,两组均在ICS的基础上再分别给予复可托或安慰剂口服,观察两组患儿RRI和哮喘发作情况、血液淋巴细胞亚群百分比及不良反应。结果复可托组的呼吸道感染次数、哮喘发作次数、发热天数、抗生素使用天数、咳嗽及气喘天数均少于对照组,差异有显著性(P<0.05)。复可托组在治疗后6个月时CD3、CD4、CD8明显升高(P<0.05);对照剂组淋巴细胞亚群百分比治疗前后比较差异无显著性(P>0.05)。两组不良反应发生率差异无显著性(P>0.05)。结论哮喘合并RRI经ICS治疗控制不佳的儿童联用复可托能有效预防RRI,减少哮喘的发作次数和严重程度;复可托冻干粉疗效肯定、无明显不良反应,对RRI或哮喘合并RRI者可考虑使用。
Objective To investigate the efficacy and safety of spleen aminopeptide oral lyophilized powder on children with bronchial asthma complicated by recurrent respiratory infection （RRI） in whom the therapy of inhaled corticosteroids （ICS） were inefficacy. Methods A double-blind randomized trial was conducted from Aug. 2004 to Aug. 2005. Fifty-six asthmatic children with RRI were randomly divided into two groups,one receiving spleen aminopeptide and the other receiving placebo,respectively. The severity of RRI and asthma,blood lymphocyte subgroup ratio,and the adverse effects were investigated in two groups. Results There was remarkable clinical responses to spleen aminopeptide with the significant reductions in the frequency of both infection and asthma episodes ,the days of fever,cough and wheeze,and the days of antibiotic therapy （ P 〈0.05 for all）. The elevation of T lymphocytes CD3 ,CD4 ,CD8 lasted for 6 months after the treatment of spleen aminopeptide comparing to those before treatment （ P 〈0.01 for all）,while having no significant changes in placebo group （ P 〉0.05 for all）. Conclusions It will be feasible that spleen aminopeptide can be used to treat children with bronchial asthma complicated by RRI with a beneficial effect.
出处
《临床儿科杂志》
CAS
CSCD
北大核心
2006年第7期600-602,共3页
Journal of Clinical Pediatrics
关键词
儿童
支气管哮喘
反复呼吸道感染
复可托
childhood
asthma
recurrent respiratory infection
spleen aminopeptide
